Potential Benefits of Second-Generation Human Papillomavirus Vaccines

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

2009 • 1,580 citations

Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta‐analysis

2008 • 922 citations

Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis

2003 • 680 citations

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years

2009 • 626 citations

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

2004 • 541 citations

The cost-effectiveness of male HPV vaccination in the United States

2011 • 199 citations

Prophylaxis of Cervical Cancer and Related Cervical Disease: A Review of the Cost-Effectiveness of Vaccination Against Oncogenic HPV Types

2010 • 148 citations

Modeling Cervical Cancer Prevention in Developed Countries

2008 • 117 citations

An update on human papillomavirus vaccine uptake among 11–17 year old girls in the United States: National Health Interview Survey, 2010

2012 • 111 citations

Effectiveness and Cost Effectiveness of Human Papillomavirus Vaccine

2009 • 93 citations

Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa

2011 • 79 citations

Human papillomavirus types in women with invasive cervical carcinoma by HIV status in Kenya

2007 • 59 citations

Chapter 17: Second generation HPV vaccines to prevent cervical cancer

2006 • 57 citations

Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia

2007 • 51 citations

The cost-effectiveness of human papillomavirus screening for cervical cancer

2005 • 51 citations

Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models

2011 • 46 citations

Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: A literature review

2008 • 46 citations

Human Papillomavirus type distribution in invasive cervical cancer in Uganda

2008 • 42 citations

Prospects for new human papillomavirus vaccines

2009 • 41 citations

Comparative evaluation of the potential impact of rotavirus versus hpv vaccination in GAVI-eligible countries: A preliminary analysis focused on the relative disease burden

2011 • 22 citations

Human papillomavirus vaccines in HIV-positive men and women

2007 • 17 citations

Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany.

2010 • 16 citations

Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany

2010 • 11 citations

CN4 HPV-BASED PRIMARY CERVICAL CANCER SCREENING IN GERMANY. COST-EFFECTIVENESS RESULTS FROM A DECISION-ANALYTIC MODELING STUDY

2010 • 1 citations

Cited By (0)

No citing papers found in database